Access Expanding For Experimental Weight Loss Drug

Drugmaker Eli Lilly says it is expanding access to its experimental weight loss drug, retatrutide, which has not been approved yet by the FDA. The company says obese patients taking the drug in clinical trials lost between 73 and 85 pounds over two years. Dr. Rachel Pessah Pollack discusses what we know about its safety, who is eligible for the medication and more.

Each weekday morning, “CBS Mornings” co-hosts Gayle King and Nate Burleson bring you the latest breaking news, smart conversation and in-depth feature reporting. “CBS Mornings” airs weekdays at 7 a.m. on CBS and stream it at 8 a.m. ET on the CBS News app.

Subscribe to “CBS Mornings” on YouTube: https://youtube.com/CBSMornings
Watch CBS News 24/7: https://cbsnews.com/live/
Download the CBS News app: https://cbsnews.com/mobile/
Follow “CBS Mornings” on Instagram: https://instagram.com/cbsmornings/
Like “CBS Mornings” on Facebook: https://facebook.com/CBSMornings
Follow “CBS Mornings” on X: https://twitter.com/CBSMornings
Subscribe to our newsletter: https://cbsnews.com/newsletters/
Try Paramount+ free: https://paramountplus.com/?ftag=PPM-05-10aeh8h

For video licensing inquiries, contact: licensing@veritone.com